Assi Levi

Prof. Dr. Assi Levi

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2018 in The Journal of Allergy and Clinical Immunology: In Practice
Verified
Journal Article
Closed access
ISIgor Snast
Igor Snast
NKNoa Kremer
Noa Kremer
MLMoshe Lapidoth
Moshe Lapidoth
CEClaes David Enk
Claes David Enk
YTYuval Tal
Yuval Tal
ALAssi Levi
Assi Levi

14 April 2020 in Dermatology
Verified
Journal Article
Closed access
PDF file
ISIgor Snast
Igor Snast
ESEran Sharon
Eran Sharon
RKRan Kaftory
Ran Kaftory
YNYehonatan Noyman
Yehonatan Noyman
MOMeital Oren-Shabtai
Meital Oren-Shabtai
ALAssi Levi
Assi Levi
Introduction: Surgery is commonly regarded as the mainstay of treatment of extramammary Paget disease (EMPD); however, nonsurgical approaches have gained popularity in recent years. Objectives: To review the published evidence for the efficacy and safety of nonsurgical modes of therapy for EMPD. Methods: A systematic review and meta-analysis of nonsurgical EMPD treatments was performed. The primary outcome was complete response (CR); secondary outcomes were clinical regression by ≥50%, adverse events, and recurrence rate. Results: The systematic review included 43 observational studies (341 patients; 7 prospective cohort studies, 19 retrospective cohort studies, and 17 cases series) evaluating 5 treatment modalities. Imiquimod (13 studies, 110 patients) administered at variable doses ranging from daily to twice weekly for 2–56 weeks demonstrated CR of 54% (95% CI, 40–67%; I2 = 37%) and had a satisfactory safety profile. In 14 heterogeneous studies (122 patients) evaluating photodynamic therapy (PDT), only 36% (95% CI, 22–53%; I2 = 52%) of patients achieved CR. Radiotherapy (12 studies, 67 patients) showed CR of 97%, but was associated with local and systemic side effects. Ablative lasers and topical fluorouracil and calcipotriene lacked adequate evidence of efficacy. Conclusions: Imiquimod and radiotherapy are the most appropriate nonsurgical modalities for EMPD treatment given their good efficacy and safety profile. PDT has limited efficacy but may be appropriate in selected clinical settings.

11 September 2015 in Pediatric Allergy and Immunology
Verified
Journal Article
Closed access
PDF file
ALAssi Levi
Assi Levi
YTY. Tal
Y. Tal
ZDZ. Dranitzki
Z. Dranitzki
MSM. Shalit
M. Shalit
CEC. D. Enk
C. D. Enk

1 August 2018 in Melanoma Research
Verified
Journal Article
Closed access
MMMichael Moshe
Michael Moshe
ALAssi Levi
Assi Levi
DADean David Ad-El
Dean David Ad-El
DBDan Ben-Amitai
Dan Ben-Amitai
DMDaniel Mimouni
Daniel Mimouni
MLMoshe Lapidoth
Moshe Lapidoth
Amelanotic melanomas (AMMs) account for a small proportion of all melanomas. They pose a risk of delayed diagnosis and, consequently, poor prognosis. AMMs may atypically present as a pyogenic granuloma-like lesion. This study sought to investigate the prevalence and clinical and histological features of AMM masquerading as pyogenic granuloma. The database of a tertiary medical center was screened for all patients pathologically diagnosed with melanoma in 2005–2016. Those with a suspected primary (i.e. pre-excision) clinical diagnosis of pyogenic granuloma were identified, and their demographic, clinical, histologic, and outcome data were collected from the medical files. Of 2038 patients diagnosed with melanoma, 10 (∼0.5%) had a pyogenic granuloma-like AMM. The mean±SD age at lesion presentation was 56±18.9 years and the mean time from lesion appearance to diagnosis was 91.5±117.1 months. Nine tumors were located on the skin surface, and one on the oral mucosa. The mean lesion size was 19.6±14.1 mm2 and the mean Breslow’s depth was 6.47±3.1 mm; all tumors presented in the vertical growth phase. Seven (70%) patients had lymph node involvement or metastasis at diagnosis. Two patients died of the disease within 1 year of diagnosis. Given the potential lethality of AMM and the benign nature of pyogenic granuloma, clinician recognition of pyogenic granuloma-like AMMs is crucial. In the presence of a pyogenic granuloma-like lesion, findings of older patient age and large tumor size should raise the index of suspicion and prompt a biopsy study, thereby ensuring early and accurate treatment.

31 July 2018 in Photodermatology, Photoimmunology & Photomedicine
Verified
Journal Article
Open access
PDF file
ALAssi Levi
Assi Levi
EHEmmilia Hodak
Emmilia Hodak
CEClaes David Enk
Claes David Enk
ISIgor Snast
Igor Snast
DSDan Slodownik
Dan Slodownik
MLMoshe Lapidoth
Moshe Lapidoth
Summary: Background: Actinic cheilitis (AC) is a common, chronic premalignant condition resulting from protracted sun exposure affecting the vermilion border of the lower lip. Treatment of AC aims at terminating the progression to squamous cell carcinoma by obliterating the primary lesion, and includes ablative methods; nonablative modalities such as cryotherapy, electrodessication, chemical peeling, topical imiquimod and 5‐fluorouracil; and photodynamic therapy (PDT). Daylight‐activated PDT, in which natural daylight serves as the light source, showed promising results in the treatment of actinic keratoses with substantially less pain than conventional PDT.Purpose: To determine the safety and efficacy of daylight PDT in a series of patients with AC.Methods: Eleven patients with AC were treated with daylight PDT. All patients underwent repeated treatment sessions until clinical and histological remission were achieved.Results: Cure rate was 91% (10 of 11 patients, three females/eight males; mean age 59.2 ± 14.4 years). Mean number of treatments to attain cure was 2.7. Patients experienced mild erythema and minimal to no pain during treatment.Conclusions: Daylight PDT is a promising modality for the treatment of AC, with impressive cosmetic results and few side effects.

2 October 2018 in Clinical and Experimental Dermatology
Verified
Journal Article
Closed access
PDF file
ISI. Snast
I. Snast
MLM. Lapidoth
M. Lapidoth
VUV. Uvaidov
V. Uvaidov
CEC. D. Enk
C. D. Enk
SMS. Mazor
S. Mazor
ALAssi Levi
Assi Levi